

**ADDRESSES:** Department of Health and Human Services, Hubert H. Humphrey Building, 200 Independence Avenue SW., Great Hall, First Floor, Washington, DC 20201. For a map and directions to the Hubert H. Humphrey building, see <http://www.hhs.gov/about/hhh.html>.

**FOR FURTHER INFORMATION CONTACT:** Any questions about meeting registration or public comment sign-up should be directed to *CFSAC@seamoncorporation.com*.

Please direct other inquiries to *cfsac@hhs.gov*.

**SUPPLEMENTARY INFORMATION:** CFSAC was established on September 5, 2002 to advise, consult with, and make recommendations to the Secretary, through the Assistant Secretary for Health, on a broad range of topics including: (1) The current state of knowledge and research and the relevant gaps in knowledge and research about the epidemiology, etiologies, biomarkers, and risk factors relating to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and identifying potential opportunities in these areas; (2) impact and implications of current and proposed diagnosis and treatment methods for ME/CFS; (3) development and implementation of programs to inform the public, health care professionals, and the biomedical research communities about ME/CFS advances; and (4) strategies to improve the quality of life of ME/CFS patients.

The agenda for this meeting is being developed and will be posted on the CFSAC Web site, <http://www.hhs.gov/advcomcfs/> when finalized. The meeting will be live-video streamed at <http://www.hhs.gov/live> and archived through the CFSAC Web site: <http://www.hhs.gov/advcomcfs/>. Listening-only via telephone will be available on both days. Call-in information will be posted on the CFSAC Web site. Individuals who plan to attend in-person should register at <http://www.blsmetings.net/CFSAC>. All registration should be completed by June 12, 2014. Attendance by visitors who are not U.S. citizens is welcome, but prior approval is required by sending a request to *CFSAC@seamoncorporation.com* before June 5, 2014. Members of the media will also need to register. All attendees will be required to show valid government-issued picture identification (state or federal) for entry into the federal building. Non-federal employees will receive a wrist band that must be worn the entire time. Security requires all non-federal employees to be escorted the entire time they are in the building.

Upon leaving the building for any reason, persons will be required to follow the security steps mentioned above and receive a new wrist band.

Members of the public will have the opportunity to provide public comment at the meeting or via telephone. International calls cannot be accommodated. You are no longer required to submit a written copy of your testimony unless you wish to have it included in the public record. Individuals wishing to provide public comment in-person or via phone will be required to request time for public comment by Monday, June 9, 2014, at the following link: <http://www.blsmetings.net/CFSAC>. An email to acknowledge receipt of the request for public comment will be sent from *CFSAC@seamoncorporation.com*. Another email will be sent by June 12, 2014, to confirm the time that has been given to each individual who is scheduled to provide public comment. Each speaker will be limited to three minutes for public comment. No exceptions will be made. Priority will be given to individuals who have not provided public comment within the previous year.

Individuals wishing to submit written comment for the public record should send an electronic copy of their written testimony to: *CFSAC@seamoncorporation.com* by June 12, 2014. The document for public record must not exceed 5 single-spaced, typed pages, using a 12-point typeface; it is preferred that the document be prepared in the MS Word format. Please note that PDF files, handwritten notes, charts, and photographs will not be posted on the CFSAC Web site, but will be available upon request at *CFSAC@seamoncorporation.com* and for public view during the CFSAC meeting at the Hubert H. Humphrey Building, Department of Health and Human Services, 200 Independence Ave. SW., Great Hall, Washington, DC 20201.

Requests to participate in the public comment session and provide written testimony will not be accepted through the CFSAC email account. Please send all questions about specific public comment requests or inquiries to *CFSAC@seamoncorporation.com*.

Only written testimony submitted for public record and received in advance of the meeting are part of the official meeting record and will be posted to the CFSAC Web site. Materials submitted should not include sensitive personal information, such as social security number, birthdate, driver's license number, state identification or foreign country equivalent, passport number, financial account number, credit or

debit card number. If you wish to remain anonymous the document must specify this.

Persons who wish to distribute printed materials in person to CFSAC members should submit one copy to the Designated Federal Officer at *cfsac@hhs.gov*, prior to June 12, 2014.

Dated: May 16, 2014.

**Nancy C. Lee,**

*Designated Federal Officer, Chronic Fatigue Syndrome Advisory Committee.*

[FR Doc. 2014-12371 Filed 5-28-14; 8:45 am]

**BILLING CODE 4150-28-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Findings of Research Misconduct

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

*Helen Freeman, Ph.D., Harvard Medical School and Beth Israel Deaconess Medical Center:* Based on an investigation conducted by Harvard Medical School (HMS) and Beth Israel Deaconess Medical Center (BIDMS) and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Helen Freeman, former HMS Postdoctoral Fellow at BIDMS, engaged in research misconduct in research supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), grant R37 DK053477.

ORI found that the Respondent engaged in research misconduct by knowingly and intentionally falsifying three (3) figures and/or legends and one (1) supplemental movie legend in a manuscript submitted for publication to the journal *Nature* (Freeman, H.C., Kong, D., Sidman, R.L., & Lowell, B. "Inhibition of UCP2 Prevents Neurodegenerative Diseases in Mice.").

Specifically, ORI found that Respondent:

- Falsified Figure 6 and its legend in a manuscript submitted to *Nature* by claiming that the experiment represented histological and rotarod results from 5 week old *pcd3f<sup>-/-</sup>* mice treated with saline or *pcd3f<sup>-/-</sup>* mice treated with genipin when the genotype, treatment conditions, numbers of mice used, and mice age were not as claimed; these falsified data also were presented to a colleague for use in related experiments

- falsified Figure 4, Supplementary Figure 3, and Supplementary Movie 1 and/or its legends in a manuscript submitted to *Nature* by claiming that the knockout of UCP2 rescues the ataxic phenotype of *pcd3f*<sup>-/-</sup> mice when she knew this to be false.

Dr. Freeman has voluntarily agreed for a period of three (3) years, beginning on May 6, 2014:

(1) To have her research supervised if employed by an institution that receives or applies for U.S. Public Health Service (PHS) funding; Respondent agreed that prior to the submission of an application for PHS support for a research project on which the Respondent's participation is proposed and prior to Respondent's participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of Respondent's duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of Respondent's research contribution; Respondent agreed that she shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed-upon supervision plan;

(2) that any institution employing her shall submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and

(3) to exclude herself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

**FOR FURTHER INFORMATION CONTACT:** Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite

750, Rockville, MD 20852, (240) 453-8800.

**Donald Wright,**

*Acting Director, Office of Research Integrity.*

[FR Doc. 2014-12442 Filed 5-28-14; 8:45 am]

**BILLING CODE 4150-31-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Healthcare Research and Quality

#### Agency Information Collection Activities: Proposed Collection; Comment Request

**AGENCY:** Agency for Healthcare Research and Quality, HHS.

**ACTION:** Notice.

**SUMMARY:** This notice announces the intention of the Agency for Healthcare Research and Quality (AHRQ) to request that the Office of Management and Budget (OMB) approve the proposed information collection project: "Voluntary Customer Survey Generic Clearance for the Agency for Healthcare Research and Quality." In accordance with the Paperwork Reduction Act, 44 U.S.C. 3501-3520, AHRQ invites the public to comment on this proposed information collection.

**DATES:** Comments on this notice must be received by July 28, 2014.

**ADDRESSES:** Written comments should be submitted to: Doris Lefkowitz, Reports Clearance Officer, AHRQ, by email at [doris.letkowitz@AHRQ.hhs.gov](mailto:doris.letkowitz@AHRQ.hhs.gov).

Copies of the proposed collection plans, data collection instruments, and specific details on the estimated burden can be obtained from the AHRQ Reports Clearance Officer.

**FOR FURTHER INFORMATION CONTACT:** Doris Lefkowitz, AHRQ Reports Clearance Officer, (301) 427-1477, or by email at [doris.lefkowitz@AHRQ.hhs.gov](mailto:doris.lefkowitz@AHRQ.hhs.gov).

#### SUPPLEMENTARY INFORMATION:

##### Proposed Project

*Voluntary Customer Survey Generic Clearance for the Agency for Healthcare Research and Quality*

This is a request for the Office of Management and Budget (OMB) to re-approve for an additional 3 years, under the Paperwork Reduction Act of 1995,

the generic clearance for the Agency for Healthcare Research and Quality (AHRQ) to survey the users of AHRQ's work products and services, OMB control number 0935-0106. The current clearance was approved on July 20th, 2011 and will expire on July 31st, 2014.

Customer surveys will be undertaken by AHRQ to assess its work products and services provided to its customers, to identify problem areas, and to determine how they can be improved. Surveys conducted under this generic clearance are not required by regulation and will not be used by AHRQ to regulate or sanction its customers. Surveys will be entirely voluntary, and information provided by respondents will be combined and summarized so that no individually identifiable information will be released. Proposed information collections submitted under this generic clearance will be reviewed and acted upon by OMB within 14 days of submission to OMB.

#### Method of Collection

The information collected through focus groups and voluntary customer surveys will be used by AHRQ to identify strengths and weaknesses in products and services to make improvements that are practical and feasible. Information from these customer surveys will be used to plan and redirect resources and efforts to improve or maintain a high quality of service to the lay and health professional public.

#### Estimated Annual Respondent Burden

Exhibit 1 shows the estimated total burden hours for the respondents. Mail surveys are estimated to average 15 minutes, telephone surveys 40 minutes, web-based surveys 10 minutes, focus groups two hours, and in-person interviews are estimated to average 50 minutes. Mail surveys may also be sent to respondents via email, and may include a telephone non-response follow-up. Telephone non-response follow-up for mailed surveys does not count as a telephone survey. The total burden hours for the 3 years of the clearance is estimated to be 10,150 hours.

Exhibit 2 shows the estimated cost burden for the respondents. The total cost burden for the 3 years of the clearance is estimated to be \$340,127.